Company Overview
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $7.25M (+1181.3% YoY); net profit $-17.41M.
- Trailing 12 Months Year-on-year growth — revenue -88.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -12.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -12.93% |
| 1 Year: | -88.30% |
Stock Price Performance
| 1 Year: | +220.51% |
| 6 Months: | +28.50% |
| 3 Months: | +16.53% |
| 1 Month: | +4.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -12.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OVID Ovid Therapeutics Inc. PHARMA | 2.75 | -13.10 | $537.07M | 0.00% | -29.75% | -25.96% | -12.93% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45M | 0 | 11.10K | 66.00K | 75.00K | 109.00K | 148.00K | 169.00K | 173.00K | 130.00K | 6.27M | 132.00K | 718.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.68M | 11.35M | 12.65M | 13.01M | 17.85M |
| Operating Income | - | -5.42M | -5.81M | - | -34.26M | -10.29M | -9.41M | - | -13.43M | -13.21M | -13.18M | - | -14.05M | -13.32M | -16.77M | - | -20.29M | -23.14M | -16.40M | 176.56M | -14.31M | -11.68M | -16.27M | -14.30M | -12.80M | -14.89M | -14.17M | -12.03M | -17.42M | -20.52M | -13.23M | -12.55M | -5.07M | -12.52M | -12.29M | -17.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.41M | -4.97M | -12.51M | -12.28M | -17.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.23M | -4.68M | -12.16M | 9.66M | -16.99M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -3.68M | -5.39M | -5.79M | -7.56M | -34.24M | -10.25M | -9.36M | -10.96M | -13.18M | -12.94M | -12.96M | -12.90M | -13.80M | -13.06M | -16.63M | -16.97M | -20.03M | -22.55M | -16.42M | 176.01M | -15.79M | -11.38M | -16.11M | -14.59M | -11.97M | -13.36M | -12.41M | -11.25M | -11.69M | 8.52M | -14.01M | -10.23M | -4.68M | -12.16M | 9.66M | -16.99M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.37 | -0.41 | -0.28 | 2.53 | -0.23 | -0.17 | -0.23 | -0.21 | -0.17 | -0.19 | -0.18 | -0.16 | -0.17 | 0.12 | -0.20 | -0.14 | -0.06 | -0.17 | 0.06 | -0.12 |
| R&D Expense | 1.13M | 1.77M | 2.70M | - | 31.28M | 6.07M | 5.90M | - | 8.47M | 8.12M | 8.54M | - | 9.34M | 9.12M | 11.60M | - | 14.63M | 16.03M | 15.88M | 16.25M | 7.68M | 4.92M | 7.83M | 6.05M | 5.18M | 6.62M | 6.00M | 5.33M | 10.40M | 12.58M | 7.86M | 6.66M | 6.46M | 5.87M | - | 11.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 12.62M | - | 1.50M | 392.00K | 566.00K | 7.25M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 57.05M | 59.67M | 62.45M | 49.69M |
| Operating Income | -13.19M | -22.54M | -65.01M | -52.93M | -61.41M | -81.43M | - | -55.55M | -59.28M | -61.88M | -42.44M |
| EBITDA | - | - | - | - | - | - | - | -54.17M | -58.71M | -61.27M | -42.17M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -54.17M | -52.34M | -26.43M | -17.41M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -13.16M | -22.41M | -64.81M | -51.98M | -60.46M | -81.04M | - | -54.17M | -52.34M | -26.43M | -17.41M |
| Diluted EPS | - | - | - | - | - | -1.39 | - | -0.77 | -0.73 | -0.37 | -0.23 |
| R&D Expense | 6.61M | 9.59M | 49.97M | 33.79M | 42.16M | 63.42M | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.03M | 89.46M | 47.65M | 80.84M | 75.93M | - | 155.27M | 144.03M | 92.17M | 150.93M |
| Current Assets | - | - | - | - | - | - | - | - | 131.38M | 109.60M | 55.94M | 74.37M |
| Cash & Equivalents | 4.85M | 69.94M | 51.94M | 87.13M | 36.49M | 41.90M | 72.03M | - | 44.87M | 27.04M | 26.30M | 13.15M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Total Liabilities | - | - | - | - | 8.84M | 10.82M | 32.29M | - | 22.99M | 56.23M | 23.94M | 20.27M |
| Current Liabilities | - | - | 3.73M | 6.02M | 8.84M | 10.53M | 22.06M | - | 6.99M | 11.47M | 10.52M | 8.29M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 16.54M | 16.00M | 14.76M | 13.42M |
| Total Equity | 4.74M | 68.07M | 49.29M | 83.44M | 38.81M | 70.02M | 43.63M | - | 132.27M | 87.80M | 68.23M | 130.66M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 70.47M | 70.69M | 71.01M | 130.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -31.47M | -45.56M | -51.09M | -51.58M | - | -55.23M | -45.78M | -55.96M | -38.33M |
| Investing Cash Flow | - | - | -47.39K | -5.36M | -30.04M | 34.65M | - | -87.88M | -2.58M | 54.59M | -49.85M |
| Financing Cash Flow | - | - | 66.70M | 286.14K | 86.54M | 47.07M | - | 180.66K | 30.54M | 622.00K | 75.21M |
| Capital Expenditure | -32.08K | -30.36K | -38.91K | -33.87K | -57.16K | -127.24K | -189.41K | -1.42M | -137.00K | -161.00K | - |
| Free Cash Flow | - | - | -31.51M | -45.59M | -51.15M | -51.71M | - | -56.65M | -45.92M | -56.12M | -38.33M |
| Net Change in Cash | - | - | - | - | - | - | - | -142.93M | -17.83M | -740.00K | -12.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -645.4% | - | -3,696.4% | -15,122.7% | -10,933.7% | -585.2% |
| Net Margin % | - | - | - | - | - | -642.3% | - | -3,604.7% | -13,351.8% | -4,670.1% | -240.1% |
| ROE % | -19.3% | -45.5% | -77.7% | -134.0% | -86.3% | -185.7% | - | -41.0% | -59.6% | -38.7% | -13.3% |
| ROCE % | - | -45.7% | -77.9% | -136.4% | -87.3% | -151.2% | - | -37.5% | -44.7% | -75.8% | -29.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.62% | 20.74M | $55.79M |
| 2 | Eventide Asset Management LLC | 6.05% | 11.81M | $31.77M |
| 3 | Blackrock Inc. | 5.54% | 10.82M | $29.12M |
| 4 | RA Capital Management, L.P. | 5.38% | 10.50M | $28.25M |
| 5 | Affinity Asset Advisors, Llc | 5.19% | 10.14M | $27.29M |
| 6 | State Street Corporation | 4.05% | 7.90M | $21.25M |
| 7 | Vanguard Capital Management LLC | 3.97% | 7.76M | $20.87M |
| 8 | Adar1 Capital Management, LLC | 3.80% | 7.42M | $19.95M |
| 9 | Balyasny Asset Management LP | 3.44% | 6.72M | $18.07M |
| 10 | Adage Capital Partners GP L.L.C. | 3.16% | 6.16M | $16.58M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OVID
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQYUFNbVR3WVUwdl9rSW5WRUh5T0U1bWp1ZFhkMDNGeG1NMlNFbzBYOTAzZTJsNTR1T1gteTlIdXpuMmVKWlprRHZaSVkwTFRpMkdDdEZHcHJQOEEwWUs5dUtvMS1HUjkyaXZiS0dtSGhkUjlPamtRcHAzWS1WUDlwZjBRTjFZZVpWSDRvN2…
Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE0zZl93VVhuR21JUmw5N0FaR2xmSEQ4cUxjRnE5NmRfZmxsMDlVX09EWjN5MFM4cmE2ZmhPOU9uSnNUa0NTdFZQZg?oc=5" target="_blank">Ovid Therapeutics Stock Price Forecast. Should You Buy OVID?</a> …
OVID Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBMeGhBS0p4SWhoeDJGTC1ZN0Fvb3VDeVNJeGQ5SWlleGU4N1N3cmI3ZmczOFR4bGRjRmFyVFBlWHIyUnI0RHBFcEZvNTJiRHRhTmE0dXR5WFRYQ2E3d2NRQVkyYVQ1Q1VFVHdFM0RGUXllX082VUcxcGZB?oc=5" target="_blank">OVI…
OVID Financials: Income Statement, Balance Sheet & Cash Flow | Ovid Therapeutics Inc - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE13MjFZNW5NcWNCbE5McVBGN1lVdW9kQ1NSVDh2OHhsZW5OclVDMnotbmZBUGViUWZvVXlzRWlwSzVBUTIxUm9OaXJ1S1NvOEFpN2hIcktn?oc=5" target="_blank">OVID Financials: Income Statement, Balance Sheet & …
$OVID stock is up 12% today. Here's what we see in our data. | OVID Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQSU1nNktfZ0JOMzVmMy1wX3oxLXdoUUJIaXA4NXlfUWZLRTlBb1B4ME0ydllCVHRKN3o3WTFXSVBETTM4dEZYQ2dMT2ZDelBvOUxaRmpOS2NGTnRjTHAwNG9WYmdoUnNab2ZhX0lRX0hVbnBwRkJmZnhUNnFUcWd4cVlSQmcyaGVCY2tPZD…
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPbnRRNmFhR2xHdm5jNzRGQWNxb3Z6aHRQXy12dVd6cEdwa01VRng5blZuOVJ2b2hoQWRqVTEyQ0pNbTNVMXJsRWpncUxPRUpQSzNKWDVSdU83MmYyck5OSjRJNVRRa0FDcVJ5SUhRcm14akh3RWZWTnFLSHdNRUNRaEdHS1hYVmg4N1BrUW…
OVID — Frequently Asked Questions
What is the current share price of Ovid Therapeutics Inc. (OVID)?
As of 2026-09-19 21:16 PDT, Ovid Therapeutics Inc. (OVID) trades at $2.75 on NasdaqCM. Its 52-week range is $0.84 to $2.96.
What is the market capitalisation of OVID?
Ovid Therapeutics Inc. (OVID) has a market capitalisation of $537.07M on NasdaqCM.
What is the P/E ratio of OVID?
OVID trades at a trailing price-to-earnings (P/E) ratio of -13.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.37.
What is the return on equity (ROE) of OVID?
OVID has a return on equity (ROE) of -25.96%. Its return on capital employed (ROCE) is -29.75%.
Is OVID a good stock to buy?
This page provides a data-driven analysis of Ovid Therapeutics Inc. (OVID), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.